866-997-4948(US-Canada Toll Free)

Metastatic Ovarian Cancer - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Ovarian Cancer

No. of Pages : 66 Pages

Metastatic Ovarian Cancer Pipeline Review, H1 2014, provides an overview of the Metastatic Ovarian Cancers therapeutic pipeline.

 

This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Content

 

 

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Ovarian Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Ovarian Cancer - Overview 8
Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis 9
Metastatic Ovarian Cancer - Therapeutics under Development by Companies 10
Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Ovarian Cancer - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Metastatic Ovarian Cancer - Products under Development by Companies 15
Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes 16
Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development 17
Daiichi Sankyo Company, Limited 17
Dainippon Sumitomo Pharma Co., Ltd. 18
Millennium Pharmaceuticals, Inc. 19
Aphios Corporation 20
Northwest Biotherapeutics, Inc. 21
VG Life Sciences, Inc. 22
Aura Biosciences, Inc. 23
Metastatic Ovarian Cancer - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
tigatuzumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
orteronel - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DCVax-L vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cell Therapy to Inhibit VEGFR-2 for Oncology - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
hydroxychloroquine + sorafenib tosylate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
APH-0912 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drugs for Metastatic Ovarian Cancer - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SM-276001 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Pseudovirions For Cancer - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Glutathione Disulfide Liposomal - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Metastatic Ovarian Cancer - Recent Pipeline Updates 49
Metastatic Ovarian Cancer - Dormant Projects 58
Metastatic Ovarian Cancer - Discontinued Products 59
Metastatic Ovarian Cancer - Product Development Milestones 60
Featured News & Press Releases 60
Mar 10, 2014: NW Bio Announces Two German Approvals: \"Hospital Exemption\" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement 60
Jan 09, 2014: Synta Announces Launch of GANNET53, a Randomized, pan-European Study of Ganetespib in p53 Mutant, Metastatic Ovarian Cancer 62
Mar 18, 2013: Merrimack Pharma Completes Enrollment In Phase II Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-resistant Or Refractory Advanced Ovarian Cancers 63
Mar 06, 2013: Ziopharm Oncology Announces Initiation Of Indiana University-sponsored Phase II Study Of Palifosfamide In Recurrent And Incurable Germ Cell Tumors 63
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Of MM-121 At European Society For Medical Oncology 2012 64
 

Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Table

 

Number of Products under Development for Metastatic Ovarian Cancer, H1 2014 8

Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2014 9

Number of Products under Development by Companies, H1 2014 11

Number of Products under Investigation by Universities/Institutes, H1 2014 12

Comparative Analysis by Clinical Stage Development, H1 2014 13

Comparative Analysis by Early Stage Development, H1 2014 14

Products under Development by Companies, H1 2014 15

Products under Investigation by Universities/Institutes, H1 2014 16

Metastatic Ovarian Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 17

Metastatic Ovarian Cancer - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 18

Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 19

Metastatic Ovarian Cancer - Pipeline by Aphios Corporation, H1 2014 20

Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2014 21

Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H1 2014 22

Metastatic Ovarian Cancer - Pipeline by Aura Biosciences, Inc., H1 2014 23

Assessment by Monotherapy Products, H1 2014 24

Assessment by Combination Products, H1 2014 25

Number of Products by Stage and Target, H1 2014 28

Number of Products by Stage and Mechanism of Action, H1 2014 31

Number of Products by Stage and Route of Administration, H1 2014 33

Number of Products by Stage and Molecule Type, H1 2014 35

Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2014 49

Metastatic Ovarian Cancer - Dormant Projects, H1 2014 58

Metastatic Ovarian Cancer - Discontinued Products, H1 2014 59

List of Chart

 

Number of Products under Development for Metastatic Ovarian Cancer, H1 2014 8

Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2014 9

Number of Products under Development by Companies, H1 2014 10

Number of Products under Investigation by Universities/Institutes, H1 2014 12

Comparative Analysis by Clinical Stage Development, H1 2014 13

Comparative Analysis by Early Stage Products, H1 2014 14

Assessment by Monotherapy Products, H1 2014 24

Number of Products by Top 10 Target, H1 2014 26

Number of Products by Stage and Top 10 Target, H1 2014 27

Number of Products by Top 10 Mechanism of Action, H1 2014 29

Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30

Number of Products by Top 10 Route of Administration, H1 2014 32

Number of Products by Stage and Top 10 Route of Administration, H1 2014 33

Number of Products by Top 10 Molecule Type, H1 2014 34

Number of Products by Stage and Top 10 Molecule Type, H1 2014 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *